

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

**IN RE: VALSARTAN LOSARTAN &  
IRBESARTAN PRODUCTS LIABILITY  
LITIGATION**

This Document Relates to All Actions

MDL No. 2875

Case No. 1:19-md-02875-RBK-JS

Honorable Robert B. Kugler,  
District Court Judge

Honorable Karen M. Williams,  
Magistrate Judge

**NOTICE OF APPEARANCE**

To the Clerk:

Please enter the appearance of Robert M. Buchholz hereby in this MDL on behalf of Defendant Sciegen Pharmaceuticals Inc. on this Court's MDL master docket, and requests to be added to the CM/ECF system list in this matter at the following email address: rbuchholz@hinshawlaw.com. I have been admitted *pro hac vice* in this Court for this matter pursuant to MDL Case Management Order No. 1.

By entering an appearance, the undersigned Defendant does not waive any defenses, and specifically preserves all defenses related to service and personal jurisdiction in any individual case that is currently pending in MDL 2875 or that subsequently may be transferred to or consolidated with MDL 2875.

Dated: March 31, 2023

Respectfully submitted,

/s/ Robert M. Buchholz

Robert M. Buchholz, BBO #685804  
HINSHAW & CULBERTSON, LLP  
53 State Street, 27<sup>th</sup> Floor  
Boston, MA 02109  
617-213-7000; 617-213-7001 fax  
rbuchholz@hinshawlaw.com

*Attorneys for Defendant  
Sciegen Pharmaceuticals Inc.*

**CERTIFICATE OF SERVICE**

I, Robert M. Buchholz, hereby certify that on March 31, 2023, the foregoing **Notice of Appearance** was filed through the ECF system and will be transmitted electronically to the registered participants as identified on the Notice of Electronic Filing (NEF).

*/s/ Robert M. Buchholz*  
\_\_\_\_\_  
Robert M. Buchholz